Antiviral metabolite 3'-deoxy-3',4'-didehydro-cytidine is detectable in serum and identifies acute viral infections including COVID-19.

COVID-19 antiviral bacterial biomarker ddhC diagnostic mass spectrometry metabolomics serum viral

Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
11 Mar 2022
Historique:
received: 28 07 2021
revised: 14 11 2021
accepted: 21 01 2022
pubmed: 8 2 2022
medline: 8 2 2022
entrez: 7 2 2022
Statut: ppublish

Résumé

There is a critical need for rapid viral infection diagnostics to enable prompt case identification in pandemic settings and support targeted antimicrobial prescribing. Using untargeted high-resolution liquid chromatography coupled with mass spectrometry, we compared the admission serum metabolome of emergency department patients with viral infections (including COVID-19), bacterial infections, inflammatory conditions, and healthy controls. Sera from an independent cohort of emergency department patients admitted with viral or bacterial infections underwent profiling to validate findings. Associations between whole-blood gene expression and the identified metabolite of interest were examined. 3'-Deoxy-3',4'-didehydro-cytidine (ddhC), a free base of the only known human antiviral small molecule ddhC-triphosphate (ddhCTP), was detected for the first time in serum. When comparing 60 viral with 101 non-viral cases in the discovery cohort, ddhC was the most significantly differentially abundant metabolite, generating an area under the receiver operating characteristic curve (AUC) of 0.954 (95% CI: 0.923-0.986). In the validation cohort, ddhC was again the most significantly differentially abundant metabolite when comparing 40 viral with 40 bacterial cases, generating an AUC of 0.81 (95% CI 0.708-0.915). Transcripts of viperin and The antiviral precursor molecule ddhC is detectable in serum and an accurate marker for acute viral infection. Interferon-inducible genes viperin and NIHR Imperial BRC; UKRI.

Sections du résumé

BACKGROUND BACKGROUND
There is a critical need for rapid viral infection diagnostics to enable prompt case identification in pandemic settings and support targeted antimicrobial prescribing.
METHODS METHODS
Using untargeted high-resolution liquid chromatography coupled with mass spectrometry, we compared the admission serum metabolome of emergency department patients with viral infections (including COVID-19), bacterial infections, inflammatory conditions, and healthy controls. Sera from an independent cohort of emergency department patients admitted with viral or bacterial infections underwent profiling to validate findings. Associations between whole-blood gene expression and the identified metabolite of interest were examined.
FINDINGS RESULTS
3'-Deoxy-3',4'-didehydro-cytidine (ddhC), a free base of the only known human antiviral small molecule ddhC-triphosphate (ddhCTP), was detected for the first time in serum. When comparing 60 viral with 101 non-viral cases in the discovery cohort, ddhC was the most significantly differentially abundant metabolite, generating an area under the receiver operating characteristic curve (AUC) of 0.954 (95% CI: 0.923-0.986). In the validation cohort, ddhC was again the most significantly differentially abundant metabolite when comparing 40 viral with 40 bacterial cases, generating an AUC of 0.81 (95% CI 0.708-0.915). Transcripts of viperin and
CONCLUSIONS CONCLUSIONS
The antiviral precursor molecule ddhC is detectable in serum and an accurate marker for acute viral infection. Interferon-inducible genes viperin and
FUNDING BACKGROUND
NIHR Imperial BRC; UKRI.

Identifiants

pubmed: 35128501
doi: 10.1016/j.medj.2022.01.009
pii: S2666-6340(22)00044-7
pmc: PMC8801973
doi:

Substances chimiques

Antiviral Agents 0
Cytidine 5CSZ8459RP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

204-215.e6

Subventions

Organisme : Medical Research Council
ID : MC_PC_12025
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206508/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R502376/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19040
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207511/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 215214/Z/19/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Anal Chem. 2016 Sep 20;88(18):9004-13
pubmed: 27479709
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Biotechnol. 2012 Oct;30(10):918-20
pubmed: 23051804
Anal Chem. 2006 Feb 1;78(3):779-87
pubmed: 16448051
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Microbiol. 2021 Mar;19(3):171-183
pubmed: 33057203
Front Microbiol. 2015 Aug 05;6:791
pubmed: 26300860
Nature. 2018 Jun;558(7711):610-614
pubmed: 29925952
Front Immunol. 2021 Mar 02;12:637164
pubmed: 33763081
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
BMC Biotechnol. 2013 Nov 20;13:104
pubmed: 24256843
Anal Chem. 2018 Mar 6;90(5):3156-3164
pubmed: 29381867
J Org Chem. 2021 Jul 2;86(13):8843-8850
pubmed: 34126010
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Proteome Res. 2020 Nov 6;19(11):4442-4454
pubmed: 32806897
Elife. 2021 Oct 07;10:
pubmed: 34617885
J Antimicrob Chemother. 2019 Feb 1;74(2):515-520
pubmed: 30445465
Anal Chem. 2021 Feb 2;93(4):1924-1933
pubmed: 33448796
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Sci Rep. 2019 Nov 27;9(1):17714
pubmed: 31776453
Wellcome Open Res. 2018 Aug 8;3:97
pubmed: 30345383
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Nature. 2021 Jan;589(7840):120-124
pubmed: 32937646
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Bioinformatics. 2019 Dec 15;35(24):5359-5360
pubmed: 31350543
Virol J. 2021 Jan 9;18(1):13
pubmed: 33422083
SLAS Discov. 2020 Dec;25(10):1141-1151
pubmed: 32660307
Crit Care Med. 2016 Sep;44(9):1649-62
pubmed: 27097292
Lancet Microbe. 2021 Nov;2(11):e594-e603
pubmed: 34423323
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Diabetes Obes Metab. 2018 Dec;20(12):2800-2810
pubmed: 29974637
Biochem Biophys Res Commun. 2016 Sep 23;478(3):1472-7
pubmed: 27581198
Bioinformatics. 2021 Jun 14;:
pubmed: 34125879
NAR Genom Bioinform. 2020 Sep;2(3):lqaa078
pubmed: 33015620
Cell Syst. 2021 Jan 20;12(1):23-40.e7
pubmed: 33096026
Infect Genet Evol. 2019 Mar;68:253-264
pubmed: 30615950

Auteurs

Ravi Mehta (R)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.

Elena Chekmeneva (E)

National Phenome Centre, Imperial College London, London SW7 2AZ, UK.
Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.

Heather Jackson (H)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.

Caroline Sands (C)

National Phenome Centre, Imperial College London, London SW7 2AZ, UK.
Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.

Ewurabena Mills (E)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.

Dominique Arancon (D)

Imperial College Healthcare NHS Trust, London W12 0HS, UK.

Ho Kwong Li (HK)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.
MRC Centre for Molecular Bacteriology & Infection, Imperial College London, London SW7 2AZ, UK.

Paul Arkell (P)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.
Imperial College Healthcare NHS Trust, London W12 0HS, UK.

Timothy M Rawson (TM)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.
Imperial College Healthcare NHS Trust, London W12 0HS, UK.
Division of Infection & Immunity, University College London, London WC1 E6BT, UK.

Robert Hammond (R)

Imperial College Healthcare NHS Trust, London W12 0HS, UK.

Maisarah Amran (M)

Imperial College Healthcare NHS Trust, London W12 0HS, UK.

Anna Haber (A)

Imperial College Healthcare NHS Trust, London W12 0HS, UK.

Graham S Cooke (GS)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.

Mahdad Noursadeghi (M)

Division of Infection & Immunity, University College London, London WC1 E6BT, UK.

Myrsini Kaforou (M)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.

Matthew R Lewis (MR)

National Phenome Centre, Imperial College London, London SW7 2AZ, UK.
Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.

Zoltan Takats (Z)

National Phenome Centre, Imperial College London, London SW7 2AZ, UK.
Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.

Shiranee Sriskandan (S)

Department of Infectious Disease, Imperial College London, London W12 0NN, UK.
MRC Centre for Molecular Bacteriology & Infection, Imperial College London, London SW7 2AZ, UK.
NIHR Health Protection Research Unit in Healthcare-associated Infection & Antimicrobial Resistance, Imperial College London, London W12 0NN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH